
CAS 1541172-75-1
:(S)-N-((S)-1-(((2R,4S)-1,2-Dihydroxy-2,6-diméthyl-3-oxoheptan-4-yl)amino)-1-oxo-3-phénylpropan-2-yl)-4-méthyl-2-((S)-2-(2-morpholinoacétamido)-4-phénylbutanamido)pentanamide
- (S)-N-((S)-1-(((2R,4S)-1,2-Dihydroxy-2,6-dimethyl-3-oxoheptan-4-yl)amino)-1-oxo-3-phenylpropan-2-yl)-4-methyl-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pe
- PR-519
- Kyprolis Impurity V
- L-Phenylalaninamide, (αS)-α-[[2-(4-morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S,3R)-3,4-dihydroxy-3-methyl-1-(2-methylpropyl)-2-oxobutyl]-
- (S)-N-((S)-1-(((2R,4S)-1,2-Dihydroxy-2,6-dimethyl-3-oxoheptan-4-yl)amino)-1-oxo-3-phenylpropan-2-yl)-4-methyl-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide
(S)-N-((S)-1-(((2R,4S)-1,2-Dihydroxy-2,6-dimethyl-3-oxoheptan-4-yl)amino)-1-oxo-3-phenylpropan-2-yl)-4-methyl-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide
CAS :(S)-N-((S)-1-(((2R,4S)-1,2-Dihydroxy-2,6-dimethyl-3-oxoheptan-4-yl)amino)-1-oxo-3-phenylpropan-2-yl)-4-methyl-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide
Degré de pureté :95%Masse moléculaire :737.93g/molCarfilzomib Impurity 2 (PR-519M16, Carfilzomib (2R,4S)-Diol)
CAS :Formule :C40H59N5O8Couleur et forme :White To Off-White SolidMasse moléculaire :737.94Carfilzomib (2R,4S)-Diol
CAS :Produit contrôléApplications Carfilzomib (2R,4S)-Diol is a derivative of Carflizomib (C183460), a second-generation proteasome inhibitor that is used as a treatment in relapsed and refractory multiple myeloma.
References Fostier, K., et al.: Oncotargets. Therap., 5, 237 (2012); Geurink, P.P., et al.: J. Med. Chem., 56, 1262 (2013); McCormack, P.L., et al.: Drugs., 72, 2023 (2012);Formule :C40H59N5O8Couleur et forme :NeatMasse moléculaire :737.93Carfilzomib (2S,4S)-Diol Hydrochloride
CAS :Produit contrôléFormule :C40H59N5O8•HClCouleur et forme :NeatMasse moléculaire :774.39Carfilzomib (2R,4S)-diol
CAS :Carfilzomib is a drug product that belongs to the class of drugs called proteasome inhibitors. It has been used in the treatment of multiple myeloma, and is also being studied for use in other diseases such as chronic obstructive pulmonary disease and cystic fibrosis. Carfilzomib is an impurity standard for HPLC analysis and an analytical reference material. It is also used as a pharmacopoeia reference material. Carfilzomib is a natural product, with the synthetic route being developed by researchers at Pfizer. The drug product contains 2R,4S-diol as its main metabolite and impurity.
Formule :C40H59N5O8Degré de pureté :Min. 95%Masse moléculaire :737.90 g/mol





